{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:48:48Z","timestamp":1783082928713,"version":"3.54.6"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR\/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations. DNA hydroxymethylation is implicated in the development of variety of diseases. DNA hydroxymethylation in gene promoters plays important roles in disease progression, drug response and clinical outcome of various diseases. Therefore in this study, we aimed to explore the role of aberrant hydroxymethylation in promoter regions of different tumor suppressor genes in relation to CML disease progression, response to imatinib therapy and clinical outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 150 CML patients at different clinical stages of the disease. Patients were followed up for 48\u00a0months and haematological\/molecular responses were analysed. Haematological response was analysed by peripheral blood smear. BCR\/ABL1 specific TaqMan probe based qRT-PCR was used for assessing the molecular response of CML patients on imatinib therapy. Promoter hydroxymethylation of the genes was characterized using MS-PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARF\n                      <jats:sup>ARF<\/jats:sup>\n                      genes characterize advanced CML disease and poor imatinib respondents. Although, cytokine signalling (SOCS1) gene was hypermethylated in advanced stages of CML and accumulated in patients with poor imatinib response, but the differences were not statistically significant. Moreover, we found hypermethylation of p14\n                      <jats:sup>ARF<\/jats:sup>\n                      , RASSF1 and p16\n                      <jats:sup>INK4A<\/jats:sup>\n                      genes and cytokine signalling gene (SOCS1) significantly associated with poor overall survival of CML patients on imatinib therapy. The results of this study are in agreement of the role of aberrant DNA methylation of different tumor suppressor genes as potential biomarkers of CML disease progression, poor imatinib response and overall clinical outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this study, we report that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARF\n                      <jats:sup>ARF<\/jats:sup>\n                      genes is a characteristic feature of CML disease progressions, defines poor imatinib respondents and poor overall survival of CML patients to imatinib therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-09481-9","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T06:03:38Z","timestamp":1649916218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival"],"prefix":"10.1186","volume":"22","author":[{"given":"Sameer Ahmad","family":"Guru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta Pervin","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Masroor Ali","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidhan Chandra","family":"koner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"issue":"9","key":"9481_CR1","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1182\/blood.V97.9.2823","volume":"97","author":"M Toyota","year":"2001","unstructured":"Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823\u20139.","journal-title":"Blood"},{"key":"9481_CR2","unstructured":"Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. - Abstract - Europe PMC [Internet]. [Cited 2020 Jul 20]. Available from: https:\/\/europepmc.org\/article\/med\/16231140"},{"issue":"4","key":"9481_CR3","first-page":"722","volume":"56","author":"JG Herman","year":"1996","unstructured":"Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56(4):722\u20137.","journal-title":"Cancer Res"},{"issue":"8","key":"9481_CR4","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, K\u00f6hler G, Wijermans P, et al. Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2019-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957\u201364.","journal-title":"Blood"},{"issue":"11","key":"9481_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1182\/blood.V77.11.2431.2431","volume":"77","author":"BD Nelkin","year":"1991","unstructured":"Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood. 1991;77(11):2431\u20134.","journal-title":"Blood"},{"issue":"1\u20132","key":"9481_CR6","first-page":"1","volume":"9","author":"Processing of sensory information","year":"1977","unstructured":"Processing of sensory information. Prog Neurobiol. 1977;9(1\u20132):1\u2013122.","journal-title":"Prog Neurobiol"},{"issue":"9","key":"9481_CR7","first-page":"1678","volume":"57","author":"JP Issa","year":"1997","unstructured":"Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 1997;57(9):1678\u201381.","journal-title":"Cancer Res"},{"issue":"17","key":"9481_CR8","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-07-0919","volume":"13","author":"G Strathdee","year":"2007","unstructured":"Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(17):5048\u201355.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"9481_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","volume":"86","author":"A Bedi","year":"1995","unstructured":"Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86(3):1148\u201358.","journal-title":"Blood."},{"issue":"7","key":"9481_CR10","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood.V91.7.2415","volume":"91","author":"L Dubrez","year":"1998","unstructured":"Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 1998;91(7):2415\u201322.","journal-title":"Blood"},{"issue":"5","key":"9481_CR11","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","volume":"91","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91(5):1700\u20135.","journal-title":"Blood"},{"issue":"4","key":"9481_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","volume":"20","author":"MS Neshat","year":"2000","unstructured":"Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20(4):1179\u201386.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"9481_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.4161\/cbt.6.6.4101","volume":"6","author":"F Belloc","year":"2007","unstructured":"Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther. 2007;6(6):912\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"9481_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood.V89.3.957","volume":"89","author":"C Selleri","year":"1997","unstructured":"Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89(3):957\u201364.","journal-title":"Blood"},{"issue":"11","key":"9481_CR15","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood.V85.11.3183.bloodjournal85113183","volume":"85","author":"J Maciejewski","year":"1995","unstructured":"Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183\u201390.","journal-title":"Blood"},{"issue":"10","key":"9481_CR16","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","volume":"101","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Talpaz M, Giles F, O\u2019Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794\u2013800.","journal-title":"Blood"},{"issue":"2","key":"9481_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","volume":"103","author":"ME O\u2019Dwyer","year":"2004","unstructured":"O\u2019Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh Y-C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103(2):451\u20135.","journal-title":"Blood"},{"issue":"5","key":"9481_CR18","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1002\/jcp.27505","volume":"234","author":"AA Asnafi","year":"2019","unstructured":"Asnafi AA, Deris Zayeri Z, Shahrabi S, Zibara K, Vosughi T. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches. J Cell Physiol. 2019;234(5):5798\u2013806.","journal-title":"J Cell Physiol"},{"key":"9481_CR19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","volume":"10","author":"S Romero-Garcia","year":"2020","unstructured":"Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA Methylation in the Resistance to Therapy in Solid Tumors. Front Oncol. 2020;10:1152.","journal-title":"Front Oncol"},{"issue":"1","key":"9481_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4(1):1\u201339.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"9481_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4103\/0019-509X.176741","volume":"52","author":"R Mir","year":"2015","unstructured":"Mir R, Ahmad I, Javid J, Zuberi M, Yadav P, Shazia R, et al. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer. 2015;52(3):314.","journal-title":"Indian J Cancer"},{"key":"9481_CR22","doi-asserted-by":"publisher","unstructured":"PDGFR\u03b1 promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India - Sameer Ahmad Guru, Rashid Mir, Musadiq Bhat, Imtiyaz Najar, Mariyam Zuberi, Mamta Sumi, Mirza Masroor, Naresh Gupta, Alpana Saxena, 2017 [Internet]. [Cited 2020 Jul 20]. Available from: https:\/\/journals.sagepub.com\/doi\/full\/https:\/\/doi.org\/10.1177\/1010428317713857","DOI":"10.1177\/1010428317713857"},{"issue":"4","key":"9481_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13577-020-00370-6","volume":"33","author":"SA Guru","year":"2020","unstructured":"Guru SA, Sumi MP, Mir R, Waza AA, Bhat MA, Zuberi M, et al. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum Cell. 2020;33(4):1099\u2013111.","journal-title":"Hum Cell"},{"key":"9481_CR24","doi-asserted-by":"publisher","unstructured":"Technical aspects and clinical applications of measuring BCR\u2010ABL1 transcripts number in chronic myeloid leukemia - Foroni - 2009 - American Journal of Hematology - Wiley Online Library [Internet]. [Cited 2020 Jul 20]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/ajh.21457","DOI":"10.1002\/ajh.21457"},{"issue":"6","key":"9481_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"10","key":"9481_CR26","doi-asserted-by":"publisher","first-page":"101042831771385","DOI":"10.1177\/1010428317713857","volume":"39","author":"SA Guru","year":"2017","unstructured":"Guru SA, Mir R, Bhat M, Najar I, Zuberi M, Sumi M, et al. PDGFR\u03b1 promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39(10):1010428317713857.","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"issue":"19","key":"9481_CR27","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898\u2013905.","journal-title":"Blood"},{"issue":"8","key":"9481_CR28","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","volume":"16","author":"AS Shet","year":"2002","unstructured":"Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16(8):1402\u201311.","journal-title":"Leukemia"},{"issue":"1","key":"9481_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.11.006","volume":"23","author":"SA Bert","year":"2013","unstructured":"Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2013;23(1):9\u201322.","journal-title":"Cancer Cell"},{"issue":"7","key":"9481_CR30","doi-asserted-by":"publisher","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","volume":"6","author":"J Jelinek","year":"2011","unstructured":"Jelinek J, Gharibyan V, Estecio MRH, Kondo K, He R, Chung W, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PloS One. 2011;6(7):e22110.","journal-title":"PloS One."},{"key":"9481_CR31","doi-asserted-by":"publisher","unstructured":"Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis [Internet]. [Cited 2020 Jul 20]. Available from: https:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/ol.2011.419","DOI":"10.3892\/ol.2011.419"},{"issue":"6","key":"9481_CR32","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/1878-0261.12191","volume":"12","author":"S Maupetit-Mehouas","year":"2018","unstructured":"Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, et al. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia. Mol Oncol. 2018;12(6):814\u201329.","journal-title":"Mol Oncol"},{"issue":"2","key":"9481_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2008.01178.x","volume":"82","author":"J Qian","year":"2009","unstructured":"Qian J, Wang Y-L, Lin J, Yao D-M, Xu W-R, Wu C-Y. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol. 2009;82(2):119\u201323.","journal-title":"Eur J Haematol"},{"issue":"8","key":"9481_CR34","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","volume":"85","author":"H Sill","year":"1995","unstructured":"Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85(8):2013\u20136.","journal-title":"Blood"},{"issue":"3","key":"9481_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","volume":"91","author":"A Serra","year":"1995","unstructured":"Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1995;91(3):625\u20139.","journal-title":"Br J Haematol"},{"issue":"8","key":"9481_CR36","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.leukres.2009.01.003","volume":"33","author":"A Avramouli","year":"2009","unstructured":"Avramouli A, Tsochas S, Mandala E, Katodritou E, Ioannou M, Ritis K, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130\u20132.","journal-title":"Leuk Res"},{"issue":"2","key":"9481_CR37","first-page":"F115","volume":"1378","author":"M Ruas","year":"1998","unstructured":"Ruas M, Peters G. The p16INK4a\/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378(2):F115-177.","journal-title":"Biochim Biophys Acta"},{"issue":"16","key":"9481_CR38","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/S0959-8049(03)00552-5","volume":"39","author":"E Nagy","year":"2003","unstructured":"Nagy E, Beck Z, Kiss A, Csoma E, Telek B, K\u00f3nya J, et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer. 2003;39(16):2298\u2013305.","journal-title":"Eur J Cancer"},{"key":"9481_CR39","doi-asserted-by":"crossref","unstructured":"Ah I. Inactivation of P16 (INK4a) Gene by Promoter Hypermethylation is Associated with Disease Progression in Chronic Myelogenous Leukaemia. J Carcinog Mutagen [Internet]. 2013 [cited 2020 Jul 20];04(02). Available from: https:\/\/www.omicsonline.org\/inactivation-of-p16-ink4a-gene-by-promoter-hypermethylation-is-associated-with-disease-progression-in-chronic-myelogenous-leukaemia-2157-2518.1000141.php?aid=14013","DOI":"10.4172\/2157-2518.1000141"},{"issue":"1","key":"9481_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5732\/cjc.011.10175","volume":"32","author":"X-T Hu","year":"2013","unstructured":"Hu X-T, He C. Recent progress in the study of methylated tumor suppressor genes in gastric cancer. Chin J Cancer. 2013;32(1):31\u201341.","journal-title":"Chin J Cancer"},{"issue":"1","key":"9481_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5732\/cjc.011.10344","volume":"32","author":"T-X Xiang","year":"2013","unstructured":"Xiang T-X, Yuan Y, Li L-L, Wang Z-H, Dan L-Y, Chen Y, et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer. 2013;32(1):12\u201320.","journal-title":"Chin J Cancer"},{"key":"9481_CR42","doi-asserted-by":"crossref","unstructured":"Ahmad Najar, I. Inactivation of RIZ1 Gene by Promoter Hypermethylation is Associated with Disease Progression and Resistance to Imatinib in Indian Chronic Myelogenous Leukemia Patients, First Study from India. J Cancer Sci Ther [Internet]. 2013 [cited 2020 Jul 20];05(02). Available from: https:\/\/www.omicsonline.org\/inactivation-of-riz1-gene-by-promoter-hypermethylation-is-associated-with-disease-progression-1948-5956.1000183.php?aid=10537","DOI":"10.4172\/1948-5956.1000183"},{"key":"9481_CR43","doi-asserted-by":"crossref","unstructured":"Hy C, Y G, G L. DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer [Internet]. Vol. 15, European journal of medical research. Eur J Med Res; 2010 [cited 2020 Jul 20]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20159667\/","DOI":"10.1186\/2047-783X-15-1-20"},{"key":"9481_CR44","doi-asserted-by":"publisher","unstructured":"Wang X, Cui N, Liu X, Ma J, Zhu Q, Guo S, et al. Identification of DAPK1 Promoter Hypermethylation as a Biomarker for Intra-Epithelial Lesion and Cervical Cancer: A Meta-Analysis of Published Studies, TCGA, and GEO Datasets. Front Genet [Internet]. 2018 [cited 2020 Jul 20];9. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fgene.2018.00258\/full","DOI":"10.3389\/fgene.2018.00258\/full"},{"issue":"12","key":"9481_CR45","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/cncr.22325","volume":"107","author":"G Lal","year":"2006","unstructured":"Lal G, Padmanabha L, Smith BJ, Nicholson RM, Howe JR, O\u2019Dorisio MS, et al. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma. Cancer. 2006;107(12):2752\u20139.","journal-title":"Cancer"},{"issue":"2","key":"9481_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ijc.20090","volume":"110","author":"Y Oshimo","year":"2004","unstructured":"Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, et al. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer. 2004;110(2):212\u20138.","journal-title":"Int J Cancer"},{"issue":"18","key":"9481_CR47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/92.18.1511","volume":"92","author":"X Tang","year":"2000","unstructured":"Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(18):1511\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"9481_CR48","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.onc.1204302","volume":"20","author":"DH Kim","year":"2001","unstructured":"Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene. 2001;20(14):1765\u201370.","journal-title":"Oncogene"},{"issue":"4","key":"9481_CR49","first-page":"1370","volume":"9","author":"SV Harden","year":"2003","unstructured":"Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(4):1370\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"9481_CR50","first-page":"827","volume":"12","author":"WS Kim","year":"2003","unstructured":"Kim WS, Son HJ, Park JO, Song SY, Park C. Promoter methylation and down-regulation of DAPK is associated with gastric atrophy. Int J Mol Med. 2003;12(6):827\u201330.","journal-title":"Int J Mol Med"},{"issue":"6","key":"9481_CR51","first-page":"1493","volume":"26","author":"H-U Schildhaus","year":"2005","unstructured":"Schildhaus H-U, Kr\u00f6ckel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol. 2005;26(6):1493\u2013500.","journal-title":"Int J Oncol"},{"issue":"4","key":"9481_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1349-7006.2003.tb01447.x","volume":"94","author":"T Waki","year":"2003","unstructured":"Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003;94(4):360\u20134.","journal-title":"Cancer Sci"},{"issue":"2","key":"9481_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000097623","volume":"74","author":"LP Tang","year":"2006","unstructured":"Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HHX, et al. An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion. 2006;74(2):85\u201390.","journal-title":"Digestion"},{"issue":"10","key":"9481_CR54","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1158\/1078-0432.CCR-05-1601","volume":"12","author":"M-S Chang","year":"2006","unstructured":"Chang M-S, Uozaki H, Chong J-M, Ushiku T, Sakuma K, Ishikawa S, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(10):2995\u20133002.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"9481_CR55","doi-asserted-by":"publisher","unstructured":"Jun-ichi Akahira 1, Youko Sugihashi, Kiyoshi Ito, Hitoshi Niikura, Kunihiro Okamura, Nobuo Yaegashi. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci. 2004;95(1):40-3. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb03168.x.","DOI":"10.1111\/j.1349-7006.2004.tb03168.x"},{"issue":"1","key":"9481_CR56","first-page":"249","volume":"61","author":"S Z\u00f6chbauer-M\u00fcller","year":"2001","unstructured":"Z\u00f6chbauer-M\u00fcller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1):249\u201355.","journal-title":"Cancer Res"},{"issue":"1","key":"9481_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/excr.2000.5134","volume":"264","author":"T Raveh","year":"2001","unstructured":"Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res. 2001;264(1):185\u201392.","journal-title":"Exp Cell Res"},{"issue":"1","key":"9481_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1349-7006.2006.00338.x","volume":"98","author":"Y Hasegawa","year":"2007","unstructured":"Hasegawa Y, Matsubara A, Teishima J, Seki M, Mita K, Usui T, et al. DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer. Cancer Sci. 2007;98(1):32\u20136.","journal-title":"Cancer Sci"},{"issue":"Supplement 1","key":"9481_CR59","first-page":"1608","volume":"130","author":"MS Sumi","year":"2017","unstructured":"Sumi MS, Ahmad G, Bhat MA, Rashid AR, Zuberi M, Gupta N, et al. RIZ1 Gene Promoter Methylation Increases with Progression of Chronic Myeloid Leukaemia to Advanced Phases. Blood. 2017;130(Supplement 1):1608\u20131608.","journal-title":"Blood"},{"key":"9481_CR60","volume-title":"O1\u201313\u20134RIZ1 negatively regulates IGF-1 expression in chronic myeloid leukemia","author":"S Guru","year":"2016","unstructured":"Guru S, Bhat M, Seethy A, Zuberi M, Sumi M, Singh P, et al. O1\u201313\u20134RIZ1 negatively regulates IGF-1 expression in chronic myeloid leukemia. 2016."},{"key":"9481_CR61","unstructured":"Inactivation of RIZ1 Gene by RIZ1 Pro704 Insertion\u2013Deletion Polymorphism and Promoter Hypermethylation is Associated With Disease Progression and Resistance to Imatinib in Indian Chronic Myelogenous Leukemia Patients - Clinical Lymphoma, Myeloma and Leukemia [Internet]. [cited 2020 Sep 29]. Available from: https:\/\/www.clinical-lymphoma-myeloma-leukemia.com\/article\/S2152-2650(14)00228-6\/abstract"},{"issue":"8","key":"9481_CR62","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3109\/10428194.2012.663086","volume":"53","author":"H Shimura","year":"2012","unstructured":"Shimura H, Mori N, Wang Y-H, Okada M, Motoji T. Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T-cell phenotype. Leuk Lymphoma. 2012;53(8):1599\u2013609.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"9481_CR63","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.7314\/APJCP.2014.15.12.4925","volume":"15","author":"X Zhai","year":"2014","unstructured":"Zhai X, Li S-J. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev APJCP. 2014;15(12):4925\u20138.","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"13","key":"9481_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12957-015-0557-y","volume":"8","author":"Z Du","year":"2015","unstructured":"Du Z, Ma K, Sun X, Li A, Wang H, Zhang L, et al. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma. World J Surg Oncol. 2015;8(13):141.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"9481_CR65","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3892\/ol.2017.6204","volume":"14","author":"E Jezkova","year":"2017","unstructured":"Jezkova E, Zubor P, Kajo K, Grendar M, Dokus K, Adamkov M, et al. Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients. Oncol Lett. 2017;14(1):758\u201366.","journal-title":"Oncol Lett"},{"issue":"4","key":"9481_CR66","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-04-2438","volume":"65","author":"H Fiegl","year":"2005","unstructured":"Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65(4):1141\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"9481_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1475-2867-13-91","volume":"13","author":"D Mengxi","year":"2013","unstructured":"Mengxi D, Qian W, Nan W, Xiaoguang X, Shijun L. Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP. Cancer Cell Int. 2013;13(1):91.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"9481_CR68","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/cancers11070959","volume":"11","author":"G Malpeli","year":"2019","unstructured":"Malpeli G, Innamorati G, Decimo I, Bencivenga M, Nwabo Kamdje AH, Perris R, et al. Methylation Dynamics of RASSF1A and Its Impact on Cancer. Cancers. 2019;11(7):959.","journal-title":"Cancers"},{"issue":"1","key":"9481_CR69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lungcan.2006.11.016","volume":"56","author":"JR Fischer","year":"2007","unstructured":"Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer Amst Neth. 2007;56(1):115\u201323.","journal-title":"Lung Cancer Amst Neth"},{"issue":"5","key":"9481_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.4103\/jcrt.JCRT_472_18","volume":"15","author":"A Goyal","year":"2019","unstructured":"Goyal A, Sahu RK, Kumar M, Sharma S, Qayyum S, Kaur N, et al. p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma. J Cancer Res Ther. 2019;15(5):1147\u201354.","journal-title":"J Cancer Res Ther"},{"key":"9481_CR71","doi-asserted-by":"publisher","first-page":"260549","DOI":"10.1155\/2014\/260549","volume":"2014","author":"A Al-Kaabi","year":"2014","unstructured":"Al-Kaabi A, van Bockel LW, Pothen AJ, Willems SM. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review. Dis Markers. 2014;2014:260549.","journal-title":"Dis Markers."},{"issue":"6","key":"9481_CR72","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3892\/ol.2012.655","volume":"3","author":"AK Jha","year":"2012","unstructured":"Jha AK, Nikbakht M, Jain V, Capalash N, Kaur J. p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett. 2012;3(6):1331\u20135.","journal-title":"Oncol Lett"},{"issue":"11","key":"9481_CR73","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/sj.leu.2401557","volume":"13","author":"T Taniguchi","year":"1999","unstructured":"Taniguchi T, Chikatsu N, Takahashi S, Fujita A, Uchimaru K, Asano S, et al. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia. 1999;13(11):1760\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"9481_CR74","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/labinvest.3780230","volume":"81","author":"N Burri","year":"2001","unstructured":"Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Investig J Tech Methods Pathol. 2001;81(2):217\u201329.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"9481_CR75","first-page":"w13065","volume":"140","author":"P-Y Chu","year":"2010","unstructured":"Chu P-Y, Yeh C-M, Hsu NC, Chang Y-S, Chang J-G, Yeh K-T. Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly. 2010;140:w13065.","journal-title":"Swiss Med Wkly."},{"issue":"6","key":"9481_CR76","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s13402-011-0056-2","volume":"34","author":"RC Sobti","year":"2011","unstructured":"Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, Bharti AC, et al. Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol Dordr. 2011;34(6):533\u201343.","journal-title":"Cell Oncol Dordr"},{"issue":"4","key":"9481_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1203\/PDR.0b013e3181d01863","volume":"67","author":"LHT Sakamoto","year":"2010","unstructured":"Sakamoto LHT, Camargo DE, B, Cajaiba M, Soares FA, Vettore AL. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. Pediatr Res. 2010;67(4):387\u201393.","journal-title":"Pediatr Res"},{"issue":"2","key":"9481_CR78","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/10799893.2011.553836","volume":"31","author":"S Hussain","year":"2011","unstructured":"Hussain S, Singh N, Salam I, Bandil K, Yuvaraj M, Akbar Bhat M, et al. Methylation-mediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley. J Recept Signal Transduct Res. 2011;31(2):147\u201356.","journal-title":"J Recept Signal Transduct Res"},{"issue":"2","key":"9481_CR79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/sj.jid.5700073","volume":"126","author":"A Marini","year":"2006","unstructured":"Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma. J Invest Dermatol. 2006;126(2):422\u201331.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"9481_CR80","first-page":"1008","volume":"40","author":"X-H Zhang","year":"2018","unstructured":"Zhang X-H, Yang L, Liu X-J, Zhan Y, Pan Y-X, Wang X-Z, et al. Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia. Oncol Rep. 2018;40(2):1008\u201316.","journal-title":"Oncol Rep"},{"issue":"4","key":"9481_CR81","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1046\/j.1365-2141.2003.04660.x","volume":"123","author":"T-C Liu","year":"2003","unstructured":"Liu T-C, Lin S-F, Chang J-G, Yang M-Y, Hung S-Y, Chang C-S. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol. 2003;123(4):654\u201361.","journal-title":"Br J Haematol"},{"issue":"3","key":"9481_CR82","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0092-8674(90)90015-7","volume":"62","author":"F Antequera","year":"1990","unstructured":"Antequera F, Boyes J, Bird A. High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines. Cell. 1990;62(3):503\u201314.","journal-title":"Cell"},{"issue":"14","key":"9481_CR83","doi-asserted-by":"crossref","first-page":"251686572098856","DOI":"10.1177\/2516865720988567","volume":"1","author":"MP Sumi","year":"2021","unstructured":"Sumi MP, Mahajan B, Sattar RSA, Nimisha, Apurva, Kumar A, et al. Elucidation of Epigenetic Landscape in Coronary Artery Disease: A Review on Basic Concept to Personalized Medicine. Epigenetics Insights. 2021;1(14):2516865720988567.","journal-title":"Epigenetics Insights."}],"updated-by":[{"DOI":"10.1186\/s12885-022-09568-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09481-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:05:03Z","timestamp":1666569903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09481-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9481"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09481-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-233868\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-022-09568-3","URL":"https:\/\/doi.org\/10.1186\/s12885-022-09568-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Ethics committee (IEC) of Maulana Azad Medical College (MAMC) and associated hospitals approved the study. Peripheral blood\/bone marrow samples were collected from the study subjects after written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the participants with\u2009\u2265\u200918\u00a0years of age before they were recruited for the study. The written informed consent was obtained from patients\u2009\u2265\u200918\u00a0years of age and from parents\/legal guardians of the patients with\u2009<\u200918\u00a0years of age.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors or any funding agency have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}